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Abstract: GA101/obinutuzumab is a novel type II anti-CD20 monoclonal antibody (mAb), which
is more effective than rituximab (RTX) in preclinical and clinical studies when used in combination
with chemotherapy. Ca2+ signaling was shown to play a role in RTX-induced cell death. This report
concerns the effect of GA101 on Ca2+ signaling and its involvement in the direct cell death induced
by GA101. We reveal that GA101 triggered an intracellular Ca2+ increase by mobilizing intracellular
Ca2+ stores and activating Orai1-dependent Ca2+ influx in non-Hodgkin lymphoma cell lines and
primary B-Cell Chronic Lymphocytic Leukemia (B-CLL) cells. According to the cell type, Ca2+ was
mobilized from two distinct intracellular compartments. In Raji, BL2, and B-CLL cells, GA101 induced
a Ca2+ release from lysosomes, leading to the subsequent lysosomal membrane permeabilization
and cell death. Inhibition of this calcium signaling reduced GA101-induced cell death in these cells.
In SU-DHL-4 cells, GA101 mobilized Ca2+ from the endoplasmic reticulum (ER). Inhibition of ER
replenishment, by blocking Orai1-dependent Ca2+ influx, led to an ER stress and unfolded protein
response (UPR) which sensitized these cells to GA101-induced cell death. These results revealed the
central role of Ca2+ signaling in GA101’s action mechanism, which may contribute to designing new
rational drug combinations improving its clinical efficacy.
Keywords: anti-CD20; GA101; calcium signaling; malignant B cells; cell death
1. Introduction
The anti-CD20 monoclonal antibody (mAb), rituximab (RTX), combined with chemotherapy,
became the standard regimen for treating non-Hodgkin lymphomas (NHL), such as diffuse large
B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) [1–
3]. However, a significant number of patients with DLBCL and most patients with FL or CLL are
resistant or relapse [4]. Given that CD20 is highly and specifically expressed on the surface of B cells,
it constitutes an ideal therapeutic target in NHL. Therefore, the development of a new anti-CD20 mAb
was the subject of intensive research over the past few years.
Currently, anti-CD20 mAbs are generally divided into two distinct classes. Type I mAbs, such as
rituximab, induce antibody-dependent cell-mediated cytotoxicity (ADCC), complement dependent
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cytotoxicity (CDC), and low levels of direct programmed cell death (PCD). Conversely, type II mAbs
potently trigger ADCC and PCD, but only weakly elicit CDC [5]. GA101/obinutuzumab is a novel
type II anti-CD20 mAb, which was more effective than RTX in preclinical studies, enhancing direct
PCD, ADCC, and B-cell depletion in whole blood, as well as antitumor action in human xenograft
models [6–8]. GA101-induced PCD was shown to involve lysosomal cell death [9] and reactive oxygen
species (ROS) production [10]. Clinical studies confirmed the increased efficacy of GA101 versus
rituximab monotherapy in CLL; however, best results were obtained using GA101 in combination with
chlorambucil or bendamustine [11,12]. In indolent B NHLs, the clinical value of GA101 in monotherapy
remains unclear [13]. Thus, a better understanding of its molecular action mechanism to identify
pertinent combination regimens to improve therapeutic outcomes is a key challenge.
Calcium ions (Ca2+) are of fundamental importance to signal transduction in animal cells,
triggering various cellular processes, such as gene transcription, secretion, cell proliferation, migration,
and apoptosis [14]. The intensity and origin of Ca2+ signaling determine its specific action. A cytosolic
Ca2+ rise may originate from intracellular Ca2+ stores or extracellular Ca2+ influx. In addition
to the endoplasmic reticulum (ER), the endolysosomal system is emerging as an important Ca2+
storage cell compartment [15,16]. Generally, a rise in cytosolic Ca2+ results from the opening
of Ca2+-permeable channels, expressed either on the plasma membrane or intracellular organelle
membranes. Store-operated Ca2+ entry (SOCE) is the major extracellular Ca2+ influx pathway in
non-excitable cells. SOCE is activated by Ca2+ release from the ER and involves two key proteins,
Orai1 and STIM1 (Stromal interaction molecule 1) [17]. STIM1 acts as an ER Ca2+ sensor, while Orai1
represents a channel-forming subunit of the plasma membrane Ca2+ release-activated Ca2+ (CRAC)
channel [18,19]. The inositol 1,4,5 trisphosphate (IP3R) and ryanodine (RyR) receptors, expressed
on the ER membrane are the archetypal intracellular Ca2+ release channels. More recently, two pore
channels (TPC) 1 and 2 were reported to be responsible for Ca2+ efflux from lysosomes [20,21].
ER Ca2+ homeostasis is critical to ER-supported functions, including protein folding and
chaperone activity. Its disruption (by Ca2+ store depletion) activates ER stress coping responses,
including unfolded protein response (UPR) [22]. The ER stress response is mediated by three sensors
integrated in the ER membrane: IRE1α (inositol-requiring enzyme 1), ATF6 (activating transcriptor
6), and PERK (protein kinase RNA-like ER kinase), in combination with the ER molecular chaperone
immunoglobulin binding protein (BiP) [23]. In the UPR, PERK phosphorylates eukaryotic translation
initiation factor (eIF2), which attenuates translation of most messenger RNA (mRNA). One exception
is ATF4 (activating transcriptor 4), inducing expression of CHOP (CCAAT-enhancer-binding protein
homologous protein) or the pro-apoptotic protein BIM. Upon prolonged, severe activation of the UPR,
cells are eliminated by apoptosis [24]. SOCE may indirectly influence ER luminal Ca2+-dependent
regulation of the UPR, since capacitive Ca2+ influx is required to replenish depleted ER Ca2+ stores.
This research investigated the effect of GA101 on Ca2+ homeostasis of NHL cell lines and primary
B-Cell Chronic Lymphocytic Leukemia (B-CLL) cells with the aim of determining the role of Ca2+
signals in GA101-induced cell death. We demonstrated that GA101 triggered a cytosolic Ca2+ increase,
involving different signaling pathways according to the cell type studied, and that this Ca2+ increase
played distinct roles in GA101-induced cell death.
2. Results
2.1. Calcium Responses Induced by GA101 in NHL Cell Lines
The addition of GA101 triggered a cytosolic Ca2+ increase in all cell lines recorded in HBSS
(Hank’s Balanced Salt Solution) containing 2 mM Ca2+, consisting of multi-peaks and/or a sustained
plateau phase, but of lower amplitude and frequency in BL2 and Raji cell lines (Figure 1, Supplemental
Figure S1A). To determine the origin of these Ca2+ responses, cells were recorded in Ca2+-free medium.
Ca2+ responses were maintained, but the areas under the curves were statistically smaller in all cell
types (Figure 1; Figure S1A), suggesting that these responses resulted from both intracellular Ca2+
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store mobilization and extracellular Ca2+ influx. To identify the membrane ion channels involved
in the GA101-induced calcium influx, SU-DHL-4 and BL2 cells stably expressing a short hairpin
RNA (shRNA) Orai1 were generated (Figure S2). Once again, Ca2+ responses induced by GA101
were significantly attenuated in Orai1 knockdown cells compared to cells expressing a non-targeting
shRNA (sh NT) (Figure 1). Moreover, cells pretreated with BTP2, a commonly-used SOCE inhibitor,
exhibited significantly lower GA101-induced Ca2+ responses (Figure S1B). These results revealed that
GA101 was able to induce an Orai1-dependent Ca2+ influx in NHL-B cells. The next step was to
determine the origin of the intracellular Ca2+ store mobilization induced by GA101. To this end, cells
were pretreated with either thapsigargin (TG, a sarco/endoplasmic reticulum Ca2+ ATPase (SERCA)
inhibitor, emptying the ER Ca2+ pool) or Ned-19 (an inhibitor of two pore channels expressed on
lysosome) and recorded in Ca2+-free medium. Pretreatment of SU-DHL-4 cells with TG, but not with
Ned-19, dramatically decreased the Ca2+ response in terms of percentage and amplitude (Figure 1A).
In contrast, in BL2 and Raji cells, Ca2+ mobilization was unaffected by TG, but abolished by Ned-19
(Figure 1B; Figure S1A). These results revealed that GA101 mobilized Ca2+ from ER in SU-DHL-4 cells
or lysosomes in BL2 and Raji cells, and subsequently activated Ca2+ influx by Orai1-dependent Ca2+
channels in all cell lines.
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Black arrows  indicate GA101 addition. Each trace represents the response of one cell and data are 
representative of at least three independent experiments. Data were processed using OriginPro 7.5 
(Origin Lab) or GraphPad prism. Cells were recorded in extracellular Hankʹs Balanced Salt Solution 
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2.2. Role of Calcium Influx in GA101-Induced Cell Death
Given that type II anti-CD20 mAbs cause a strong homotypic adhesion leading to cell aggregation,
it was suggested by Golay et al. [25] that the analysis of the cell death induced by these Abs using flow
cytometry should be interpreted with caution. Other studies clearly showed that cell death could be
detected after GA101 treatment by various techniques including flow cytometry [5,26]. In a preliminary
approach, we analyzed and compared cell death induced by GA101 by microscopy and flow cytometry
after propidium iodide (PI) labeling, two conventional techniques. As shown in Figure S3A, GA101
triggered cell death in all cell lines tested, and the increase in dead cells detected by both methods was
of the same order. Thus, regardless of the cell death detection technique used, we observed that BL2
cells were the most sensitive to GA101-induced cell death, while SU-DHL-4 cells were the least. Flow
cytometry allowed a rapid analysis of thousands of cells; in the further experiments, cell death was
measured using this technique.
Orai1-dependent Ca2+ influx was reported to exert a negative feedback on RTX-induced
apoptosis [27]. Therefore, we examined whether the same type of mechanism was activated by
GA101. In BL2 and Raji cells, Orai1 knockdown or BTP2 pretreatment had no effect on GA101-induced
cell death (Figure 2A; Figure S3B). In contrast, BTP2 and, to a lesser extent, the downregulation of
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Orai1 improved the efficacy of GA101 for inducing cell death in SU-DHL-4 cells, (Figure 2B); however,
only Orai1 knockdown increased their sensitivity for GA101 (half maximal efficacy concentration
(EC50) Control = 0.037 ± 0.005 vs. BTP2 = 0.036 ± 0.002 µg/mL, p > 0.05; EC50 Sh NT = 0.040 ± 0.002
vs. Sh Orai1 = 0.018 ± 0.002 µg/mL, p < 0.05) which is likely attributable to the higher specificity of Sh
Orai1 than BTP2 to inhibit Ca2+ influx. The effects of Orai1 inhibition on GA101-induced cell death in
SU-DHL-4 were not due to CD95 engagement since, unlike RTX [27], GA101 was unable to induce
CD95 capping formation, a hallmark of CD95 pathway activation (Figure S4).
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Figure 2. I olve ent of store-operated Ca2+ -i ce ll t . .
(B) SU-DHL-4 cel s. Left panels: el s ere incubated ith GA101 in the presence or absence of BTP2
(10 µM) for 24 h. Right panels: ells ex ressi s r s r i r tre t it f .
Cel death was as es ed by measuring the los of mitochondrial membrane potential (∆ψ ), using
tetramethylrhodamine methyl est r (TMR ) as a fluorescent dy , or by caspase 3 activation, measured
by the FAM-FLICA in vitro caspase detection kit and both analyzed by flow cytometry; * p < 0.05.
Disruption of ER Ca2+ homeostasis by SERCA inhibition (TG) or Ca2+ influx inhibition leads to the
accumulation of unfolded proteins and causes ER stress likely to promote cell death [28]. To envisage
the involvement of Orai1 inhibition-dependent ER stress in the potentiation of the cell death induced
by GA101, we investigated the impact of GA101 on the activation of UPR in cells expressing sh NT
or sh Orai1 (SU-DHL-4 and BL2) or after treatment with BTP2 (Raji). To this end, we studied eIF2α
phosphorylation and the expression of BIM, one of the targets transcriptionally regulated by CHOP.
Our results revealed an increase in eIF2α phosphorylation in under-expressing Orai1 SU-DHL-4 cells
treated with GA101. In contrast, no effect of Orai1 under-expression or i hibition was observed in
BL2 or Raji cells, respectively (Figure 3; Figure S5A). In agreement with these data, we found that
BIM expression increased in SU-DHL-4, while, in BL2 or Raji cells treated with GA101, it decreased
with time (Figure 3; Figure S5A). Moreover, we showed that tunicamycin, a main ER stress inducer,
sensitized the SU-DHL-4 cell line to GA101-induced cell deat but not BL2 or Raji cell lines (Figure S5B).
These results reveal a distinctive role of Ca2+ entry in GA101-induced cell death, according to the cell
line studied. In SU-DHL-4, Ca2+ entry repressed cell death by preventi g ER stress activation, while,
in BL2 a d Raji cell lines, Ca2+ influx was not, apparently, involved in GA101-induced cell death.
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Figure 3. Differential activation of endoplasmic reticulum (ER) stress in SU‐DHL‐4 and BL2 cell lines. 
(A) Cells expressing sh NT or sh Orai1 were treated with GA101 (1 μg/mL) for varying  lengths of 
time. After lysis, phosphorylated eukaryotic translation initiation factor alpha (P‐eIF2), eIF2, and 
BIM expression levels were assessed by immunoblot analysis. GAPDH was used as a loading control. 
(B) Quantification of Western blots is given as means ± SE of three to five independent experiments; 
* p < 0.05. 
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effect was observed in SU‐DHL‐4 cells or when HBSS was applied to the cell preparation instead of 
GA101  (Figure  4(Aa,Ab,Ba,Bb);  Figure  S6A,B).  These  observations  were  confirmed  after 
quantification of the fluorescent signal, by calculating the slope of the fluorescence  leakage before 
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S6B,C). These data suggested  that Ca2+ efflux  from  lysosomes by TPC was upstream of LMP and 
participated in this process. To determine whether the lysosomes released their contents in response 
to GA101, we performed  immunofluorescence staining of cathepsin B, a  releasable component of 
lysosomes. As expected, these experiments confirmed an increase in cathepsin B release in the cytosol 
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Figure 3. Differential activation of endoplasmic reticulum (ER) stress in SU-DHL-4 and BL2 cell lines.
(A) Cells expressing sh NT or sh Orai1 were treated with GA101 (1 µg/mL) for varying lengths of
time. After lysis, phosphorylated eukaryotic translation initiation factor alpha (P-eIF2α), eIF2α, and
BIM expression levels were assessed by immunoblot analysis. GAPDH was used as a loading control.
(B) Quantification of Western blots is given as means ± SE of three to five independent experiments;
* p < 0.05.
2.3. Role of Lysosomes in GA101-Induced Cell Death
Previous works reported the key role of lysosomal membrane permeabilization (LMP) in type II
anti-CD20 mAb-induced cell death [9,29,30], and ur data suggest that GA101 m bilized lysosomal
Ca2+ in the BL2 a Raji but not the SU-DHL-4 cell line. To confirm e effect of GA101 on lysoso es,
LMP was measured in all cell lines by the decrease in lysotracke fluorescence using videomicroscopy.
GA101 provoked a rop in ysotracker fluoresc nce in BL2 a d Raji cells, while no effect was
obs rved in SU-DHL-4 cells or when HBSS was applied to the cell preparation instead of GA101
(Figure 4(Aa,Ab,Ba,Bb); Figure S6A,B). Thes observations were confirm d aft r quantifica ion
the fluorescent signal, by calculating the slope of the fluorescence leakage before and after GA101
application. This analysis clearly revealed that GA101 induced a significant increas in the slop
ratio in BL2 and Raji but ot SU-DHL-4 ells, confirming the activation of LMP in BL2 a d Raji
bu not SU-DHL-4 cells (Figure 4(Ac,Bc); Figure S6C). M reover, the pre-incubation of BL2 or
Raji cells with Ned-19 significantly reversed GA101-induced LMP (Figure 4(Ab,A ,B ,Bc); Figure
S6B,C). These data suggested th t Ca2+ efflux from lysosomes by TPC was upstream of LMP and
participated in this proces . To determin whether the lysosomes released their contents in response
to GA101, we performed immunofluorescence staining f cathepsin B, a releasabl component of
lysosomes. As expected, these experiments confirmed an increase in cathepsin B release in the cytos l
of BL2 c lls, similar o that observed with the lysosomotropic agent, siramesine, used as a positive
control (Figure 4Ad). Note that no cathepsin B release was observ d in SU-DHL-4 cells (Figure 4Bd).
Pretreatment of BL2 cells with Ned-19 inh bited the GA101-induce cytosolic release of cathepsin B
(Figure 4Ad). Finally, we confirmed that LMP was involved in cell dea h induced by GA101 in BL2
and Raji but not SU-DHL-4 cells, since pretreatment with Ned-19 and E64D, a athepsin B inhibitor,
reduced GA101-induced apoptosi (Figu 4(Ae,Be); Figure S6D).
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In agreement with our calcium-signaling investigations, we revealed that, in BL2 and Raji cells,
GA101 activated the release of lysosomal Ca2+ leading to the LMP induction and cathepsin B release
responsible for cell death. In contrast, in the SU-DHL-4 cell line, GA101 activated a signaling pathway,
involving Ca2+ influx and ER stress, without the lysosomal pathway playing a major role.
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Figure 4. Differential involvement of lysosomal membrane permeabilization (LMP) in (A) BL2 cells
and (B) SU-DHL-4 cells. (a) Control recordings of lysotracker fluorescence in HBSS containing 2 mM
Ca2+. Insert: Lysotracker fluorescence slope quantification over time. (b) Effect of GA101 on LMP.
The fluorescence of lysotracker red DND-99 was recorded by videomicroscopy (Zeiss LSM 510) using
a 63× objective. Black arrows indicate HBSS or GA101 (10 µg/mL) addition. Each trace represents
the mean ± SE of three independent experiments. After pretreatment (in blue) or not (in red) with
Ned-19 (10 µM) for 45 min, cells were recorded in HBSS containing 2 mM Ca2+. (c) Quantification
of the lysotracker fluorescence slope before and after the addition of GA101 in BL2 and SU-DHL-4.
(d) Confocal microscopy of cathepsin B staining (red). After treatment, BL2 or SU-DHL-4 cells were
fixed and stained with anti-cathepsin B, revealed by donkey anti-goat Ab coupled to Alexa 594. Nuclei
were counterstained with Hoechst 33258. Siramesine was used as positive cathepsin B release inducer.
Scale bar: 10 µm. (e) Effect of LMP induced by GA101 on cell death. Cells were incubated with GA101
in the presence or absence of Ned-19 or E64D for 24 h. Cell death was assessed by measuring the loss
of mitochondrial membrane potential (∆Ψm), using TMRM as a fluorescent dye, and then analyzed by
flow cytometry; * p < 0.05.
2.4. Effect of GA101 on Primary B-CLL
Given that the most encouraging results in clinical trials with GA101 were obtained in patients
with B-CLL and t at B-CLL is closely related to lymphocytic ymp oma, which is classifi as indolent
non-Hodgkin’s lymphoma, we tested the ffect of GA101 on the death of B-CLL cells harve ted from
patient blo d samples (Table 1). GA101 induc significant cell death in 15 out of 23 B-CLL sample
tested (Table 1). Th induction of cell de th by GA101 is apparently depe dent on CD20 expression,
since CD20 expr ssion w s higher in responsive than non-responsive B-CLL (Figure 5A). We further
investigated the effects of GA101 on [Ca2+]i of 10 CLLs responsive to GA101-induced c ll death.
GA101 trigger d an intracellular Ca2+ increase in all CLLs tested. These a2+ responses were due to
both intracellul r Ca2+ mobilization and extracell lar Ca2+ e try (Figure 5B,C). We then det rmined
the rigin of GA101-induced Ca2+ mobilization. To this end, cells from six B-CLL sampl s were
pr treate with N -19 or TG and then recorded in Ca2+-free medium. In three CLL samples, Ned-19
co l tely block d GA101-induc Ca2+ mobilization, while it was unchang d after TG pre-treatment.
In contrast, in the three other B-CLL samples tested, Ca2+ response was inhibit d after TG pretr atment
but not after Ned-19 treatment (Figure 5B,C). These data sugg ted that the Ca2+ re ponse to GA101
of some CLL s mples was like that of BL2 and Raji cell lines, while ot rs beh ved like SU-DHL-4
cells. To decipher the molecular mechanisms responsible for the activation of lysosomal Ca2+ release
or not in cells, we investigated the ex r ssion of CD20, CD38, TPC1, and TPC2 pr teins. However,
no difference was observed between GA101-induced lysosomal Ca2+ release cells or not (Figure 5D;
Figure S7).
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Table 1. B-CLL patient information; GA101 1µg/mL for 24 h; * p < 0.05.
Clinical Characteristics GA101-Induced Cell
Death in CD19pos
Cells (% of Control)Patient ID Age/Gender Stage
TP53
(del17p)
%
WBC
%
CD19pos
CLL1 79/F A Positive 78 91.2 9.7 *
CLL2 73/F C Positive 69 82.1 2
CLL3 77/F A Negative 55 82 −15.7
CLL4 60/F A Negative 35 66 22 *
CLL5 79/F C Negative 56 76.8 6.9 *
CLL6 75/M A Negative 24 56.7 8.2 *
CLL7 79/F A Negative 45 23 0.2
CLL8 66/F A Negative 34 50.4 5.2 *
CLL10 62/F A Negative 39 66 −2
CLL11 86/F A Negative 86 92 1.8
CLL12 70/F A Negative 33 68 10.7 *
CLL13 66/F A Negative 36 66 15.8 *
CLL14 73/F A Negative 38 63 7 *
CLL15 56/M A Negative 23 51 −1.5
CLL16 67/M A Negative 58 76 1
CLL17 43/F A Negative 36 69 16.9 *
CLL18 73/F A Negative 41 81 −1.2
CLL19 54/M A Negative 55 73 4 *
CLL20 51/F A Negative 24 47 6.2 *
CLL21 74/F B Postive 69 92 6.8 *
CLL22 70/M A Negative 69 85 7.5 *
CLL23 49/M B Negative 52 87 9.1 *
CLL24 75/M B Negative 62 86 5.9 *
F: female, M: male, CLL: Chronic lymphocytic leukemia, WBC: White blood cells.
The next step was to investigate the involvement of Ca2+ signaling in GA101-induced cell death
in B-CLL samples. Due to the toxicity of pre-treatments on some B-CLL samples, the effects of BTP2
and Ned-19 on GA101-induced cell death were analyzed in nine B-CLL samples. In one out of nine
B-CLL samples, no treatment had any effect on GA101-induced cell death (CLL 19). In four CLL
samples (CLL5, CLL17, CLL23, and CLL24), Ned-19 statistically inhibited cell death (Figure 5E). Finally,
we observed that BTP2 had no effect (CLL 19 and CLL 23) or inhibited GA101-induced cell death
(CLL17, CLL20, CLL14, CLL13, CLL5 and CLL22) (Figure 5E,F). We hypothesized that this latter result
may be due to B-CLL resistance to ER stress. Thus, we tested the effects of tunicamycin on basal and
GA101-induced cell death in five B-CLL samples. Our results revealed that tunicamycin did not induce
cell death in B-CLL or sensitize cells to GA101 (Figure 5G), suggesting that CLL may be resistant to
ER stress.
Cancers 2019, 11, 291 10 of 18
Cancers 2019, 11, x  10  of  18 
 
 
Figure 5. Involvement of Ca2+ influx and LMP in GA101‐induced cell death in primary B‐Cell Chronic 
Lymphocytic Leukemia (B‐CLL). (A) Relationship between CD20 expression and the effect of GA101 
on cell death  in primary human B‐CLL. Immediately after  isolation peripheral blood mononuclear 
cells  (PBMC)  were  co‐immunostained  with  anti‐CD20‐FITC  and  anti‐CD19‐PE.  The  mean 
fluorescence intensity of CD20 was measured by flow cytometry in CD19‐positive (CD19pos) gated 
cells. PBMCs were incubated with GA101 1 μg/mL for 24 h, and cell death was assessed by measuring 
Figure 5. Involvement of Ca2+ influx and LMP in GA101-induced cell death in primary B-Cell Chronic
Lymphocytic Leukemia (B-CLL). (A) Relationship between CD20 expression and the effect of GA101
on cell death in primary human B-CLL. Immediately after isolation peripheral blood mononuclear
cells (PBMC) were co-immunostained with anti-CD20-FITC and anti-CD19-PE. The mean fluorescence
intensity of CD20 was measured by flow cytometry in CD19-positive (CD19pos) gated cells. PBMCs
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were incubated with GA101 1 µg/mL for 24 h, and cell death was assessed by measuring the loss
of mitochondrial membrane potential (∆Ψm), using TMRM as a fluorescent dye, and analyzed in
CD19pos cells by flow cytometry. Cells were considered responders when GA101 induced a statistically
significant increase in cell death (Mann–Whitney U; p < 0.05 considered as significant). Representative
Ca2+ responses to GA101 (10 µg/mL) in CLL involving (B) TG-sensitive (CLL20) or (C) Ned-19-sensitive
Ca2+ pools (CLL23) recorded in HBSS containing 2 mM Ca2+ (2Ca), in Ca2+-free extracellular medium
(0Ca), after pretreatment with TG (100 nM, 45 min) and recorded in Ca2+-free extracellular medium
(0Ca + TG), or after pretreatment with Ned-19 (10 µM, 1 h) and recorded in Ca2+-free extracellular
medium (0Ca + Ned19). Histograms represent areas under curves calculated under various recording
conditions, between the application time of GA101 and t = 2000 s; * p < 0.05. Ca2+ responses were
recorded as described in Figure 1. (D) Relationship between CD20 expression and GA101-induced
activation or not of lysosomal Ca2+ release in B-CLL. (E) B-CLL samples showing lysosome-dependent
or (F) independent GA101-induced cell death. (G) Effect of ER stress inducer on B-CLL cell death.
In GA101-responsive B-CLL samples, cells were incubated with GA101 (1 µg/mL) in the presence or
absence of tunicamycin 10 ng/mL for 24 h. Cell death was assessed as described above; * p < 0.05.
3. Discussion
The role of Ca2+ in cell death was extensively investigated [31]; however, its pro- or anti-apoptotic
effects seem highly dependent on the stimulus and cell type, as well as the Ca2+ toolkit that enables
cells to specifically regulate Ca2+-dependent cell death. Here, we investigated the effect of GA101 on
Ca2+ signaling and its involvement in the direct cell death evoked by GA101. We identified some key
findings: (1) GA101 triggered an intracellular Ca2+ increase by mobilizing intracellular Ca2+ stores
and activating Orai1-dependent Ca2+ influx in the three studied NHL cell lines; (2) lysosomal Ca2+
release and subsequent LMP were responsible for the cell death induced by GA101 in BL2 and Raji
but not in SU-DHL-4 cells; (3) in SU-DHL-4 cells, cell death was repressed by Orai1-dependent Ca2+
influx and, consequently, enhanced by Orai1 inhibitors through the activation of UPR in response to
ER stress; (4) in B-CLL, GA101 triggered an intracellular Ca2+ increase involving mobilization of either
lysosomal or ER Ca2+ pools and a Ca2+ influx, which are differentially implicated in GA101-induced
cell death. Taken together, these results revealed the central role of GA101-induced Ca2+ signaling in
its action mechanism.
GA101 was found to activate two distinct Ca2+ responses: one similar to that described with
RTX [27], involving ER Ca2+ store mobilization and capacitive Ca2+ influx in SU-DHL-4 cells, and
another involving lysosomal Ca2+ release and extracellular Ca2+ influx, in BL2 and Raji cell lines.
Lysosomes express Ca2+ channels, including TPC1 and TPC2, which are activated by NAADP
(Nicotinic acid adenine dinucleotide phosphate) [32–34]. In BL2 and Raji cells, Ned-19, a NAADP
receptor antagonist, was found to suppress Ca2+ mobilization triggered by GA101, suggesting that
GA101 induces NAADP formation and TPC-dependent Ca2+ release from lysosome. Moreover,
this lysosomal Ca2+ release is probably involved in LMP, since LMP was significantly inhibited by
pre-treatment with Ned-19. Interestingly, these two Ca2+ signaling pathways were also observed in
B-CLL with a ratio of 50/50. In order to identify which molecular mechanism determined the type
of Ca2+ responses activated by GA101 in cells, we evaluated the expression of various proteins in
NHLB cell lines and B-CLL. Unlike for the induction of cell death by GA101 which is related to CD20
expression level, no difference in CD20 expression was observed between lysosomal responsive cells or
not. Another explanation could be that CD38 expression, which is responsible for the transformation
of NAD+ (Nicotinamide adenine dinucleotide) to the active second messengers NAADP and cADPr
(cyclic ADP ribose) [35], may be differentially expressed in B-NHL and B-CLL cells, constituting
a switch between the two GA101-activated signaling pathways; however, this hypothesis was not
confirmed by our results obtained in cell lines and tested B-CLL. Similarly, TPC1 and TPC2 expression
was unchanged between cells. However, these data should be confirmed in a larger cohort of B-CLL.
Finally, we cannot exclude that the different Ca2+ responses induced by GA101 are due to the origin of
the NHL (DLBCL or Burkitt lymphoma) or B-CLL. Further experiments will be necessary to identify
the molecular process responsible for activating or not LMP pathway in these cells.
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We and others [36,37] showed that RTX-induced Ca2+ response in NHLB was due to IP3-
dependent intracellular Ca2+ mobilization and Orai1-dependent Ca2+ influx, while we demonstrated
that GA101 was able to trigger at least two different molecular pathways for Ca2+ signaling according
to the cell type, which could contribute to its better clinical efficacy than RTX. Indeed, type I CD20
antibody RTX and type II CD20 antibody GA101 differ fundamentally in their interaction with CD20,
which may account for activation of various transduction pathways, including Ca2+ signal kinetics
and/or more or less antibody efficiency [38].
In human primary B-CLL samples, we observed heterogeneity in cell death responses induced
by GA101, which may be due to individual variability in CD20 expression or to BCR (B-cell receptor)
functional signaling and/or to IGHV (immunoglobulin heavy-chain variable region) mutational
status. Indeed, CLL IGHV mutational status reveals bifurcation of responses toward proliferation
or anergy [39], and one can hypothesize that anergic mutated IGHV CLL cells could be more
sensitive to GA101-induced cell death than proliferative unmutated IGHV CLL because their increased
susceptibility to apoptosis. Further experiments should be necessary to elucidate this point.
It was previously shown that GA101 triggered LMP and the subsequent cathepsin release
responsible for protein cleavage (including caspases) and cell death [9,40]. We confirmed this
mechanism and suggest that LMP and cell death are, at least partly, initiated by lysosomal Ca2+
release, since Ned-19 inhibited LMP and GA101-induced cell death in BL2, Raji cells, and in half of
B-CLL samples. In contrast, in the SU-DHL-4 cell line, GA101 was unable to trigger LMP. Based on
the slope of lysotracker fluorescence in resting conditions (before GA101 application) being higher
in SU-DHL-4 than those observed in BL2 and Raji cells, it could be possible that LMP could not be
observed in these cells. However, this absence of LMP is correlated with the lack of lysosomal Ca2+
mobilization, with the absence of cathepsin release in response to GA101 and with no effect of Ned-19
or E64D on cell death induced by GA101 suggesting that lysosomal cell death is not activated by GA101
in these cells. In SU-DHL-4 cells, Orai1-dependent Ca2+ influx was clearly shown to repress sensitivity
to GA101-induced cell death, since pharmacological or genetic inhibition of Orai1 activity improved
the effect of GA101. This repressive effect of the Orai1-dependent Ca2+ influx on GA101-induced
cell death is similar to that observed with RTX; however, in contrast to RTX, this effect was not
attributable to Ca2+ inhibition of CD95 engagement [27,41], but rather the impediment of ER stress.
Indeed, Orai1 inhibition increased the phosphorylation level of eIF2α, as well as the expression of
BIM, two ER-stress markers [28]. In the SU-DHL-4 cell line, GA101 triggered ER Ca2+ store release,
but activated capacitive Ca2+ influx, thus refilling the Ca2+ stores and preserving Ca2+ homeostasis and
the efficiency of ER. When this Ca2+ influx was inhibited, the reticular Ca2+ concentration remained
low, inducing accumulation of unfolded proteins, causing ER stress and BIM expression to increase,
which promoted cell death [28,42] In BL2, Raji, and B-CLL cells, although GA101 triggered a Ca2+
influx, its inhibition did not sensitize cells to GA101-induced cell death. Two hypotheses may explain
this result. The first is that BL2, Raji, and B-CLL cells are resistant to ER stress, as suggested by
experiments where ER-stress inducers were unable to induce cell death or potentiate GA101-induced
cell death. This resistance to ER stress may be due to Bcl-2 overexpression, as already described in
B-CLL [43,44], which, by interacting with IP3R [45], may repress ER Ca2+ release and, in turn, protect
cells from ER stress. The second possibility is that Orai1-dependent Ca2+ entry is not the main source
of Ca2+ influx in these cells, but other Ca2+ channels, such as TRPC (Transient Receptor Potential
channels Canonical) [46] or TRPV (Transient Receptor Potential channels Vanilloid) [47] channels, may
be significant contributors to Ca2+ entry.
4. Materials and Methods
4.1. Reagents and Antibodies
GA101 was kindly provided by Roche Glycart AG. Thapsigargin and tunicamycin were purchased
from Merck Millipore (Fontenay s/s bois, France). BTP2, Ned-19 trans, and puromycin were supplied
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by Tocris Bioscience (Lille, France). Hoechst 33258 and siramesine were purchased from Sigma-Aldrich
(L’Isle d’Abeau, France). Tetramethylrhodamine methyl ester (TMRM) and lysotracker red DND-99
were from ThermoFisher Scientific (Courtaboeuf, France), and Fluo2-leak resistant (LR)- acetoxymethyl
ester (AM) was from Euromedex (Mundolsheim, France). FAM-FLICA in vitro caspase 3 detection kits
were supplied by AbD Serotec (Kidlington, UK).
Anti-human Orai1 rabbit polyclonal antibody was from Alomone Labs (Jerusalem, Israel).
The anti-human CD19-PE, CD19-488 (clone HIB19), and anti-human CD20-FITC (clone 2H7) and
their respective isotype controls were provided by eBiosciences (San Diego, CA, USA). Anti-cathepsin
B and anti-BIM were supplied by Santa Cruz Biotechnology (Heidelberg, Germany). The anti-phospho
eIF2α and anti-eIF2α were from Cell Signaling Technology (Ozyme, France). Alexa 594-conjugated
donkey anti-goat came from Life Technologies (Saint Aubin, France). Horseradish peroxidase
(HRP)-conjugated goat anti-mouse and goat anti-rabbit were from ThermoFisher Scientific.
4.2. Patient Samples and Cell Lines
Patients were recruited under the Institut Bergonié Institutional Review Board approval
(n◦2013-H-001, date 12-02-2013) and informed consent process, in accordance with the Declaration
of Helsinki. For B-cell chronic lymphocytic leukemia (B-CLL), peripheral blood mononuclear cells
(PBMCs) were isolated from whole blood by Ficoll gradient centrifugation, washed and cultured
in RPMI 1640 (Life Technologies) supplemented with 10% FBS (Fetal Bovine Serum). All B-CLL
samples were tested for cell death in response to GA101. The other tests (Ca2+ measurements and/or
pharmacological studies) were performed on GA101-responsive B-CLL according to the quantity of
biological material available. For Ca2+ measurement and flow cytometry experiments, B cells were
identified after staining with fluorescent anti-CD19 antibody. The BL2 and Raji Burkitt lymphomas
and SU-DHL-4 FL-transformed cell lines were obtained from the DMSZ (Deutsche Sammlung von
Mikroorganismen und Zellkulturen) cell collection (Braunschweig, Germany).
4.3. Short Hairpin RNA Lentivirus Transduction
The short hairpin RNA (shRNA) lentivirus transduction approach was used to knockdown orai1
gene expression. pLKO1 lentiviral vectors expressing DNA sequences encoding for Orai1 shRNA
(TRCN0000165044 and TRCN0000161221) were purchased from Sigma-Aldrich. Non-targeting shRNA
(sh NT) was used as a lentivirus cell transduction control. Lentiviruses were produced as previously
described [27]. The titer of each lentiviral batch was determined on various cell lines. Transduced cells
were selected by puromycin treatment.
4.4. Apoptosis Assays
B-cells were untreated or pretreated with various pharmacological agents for 1 h and then
incubated with or without GA101 for 24 h. Apoptosis was detected by the loss of mitochondrial
membrane potential using TMRM as a fluorescent dye. TMRM is a fluorescent lipophilic cation which
accumulates in hyperpolarized mitochondria of living cells, but not in depolarized mitochondria
of apoptotic cells [48]. Thus, after treatment, cells were incubated with 200 nM TMRM for 20 min,
and the loss of cell fluorescence, corresponding to apoptotic cells, was measured by flow cytometry.
Apoptosis was also assessed by measuring the percentage of cells with active caspase 3, detected
by the FAM-FLICA in vitro caspase detection kit, used according to the manufacturer’s instructions.
Apoptotic cells were analyzed by flow cytometry using a FacsCalibur cytometer and Cell Quest
software (BD biosciences, Le Pont de Claix, France).
4.5. Intracellular Calcium Measurement
For single-cell [Ca2+]i measurement cells were loaded with 7.5 µM Fluo2- LR-AM (λex: 488 nm,
λem 515 nm) calcium dye, which exhibits limited compartmentalization in intracellular stores
and is leakage resistant, in the presence of 0.02% pluronic F127 in HBSS at room temperature for
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25 min. The cells were rinsed with HBSS and incubated without Ca2+ probe for 15 min to complete
de-esterification of the dye. For B-CLL, cells were previously labeled with anti-human CD19 APC
(Allophycocyanin) at room temperature for 20 min, to ensure that Ca2+ recordings originated from
B cells. In some experiments, cells were placed in a Ca2+-free HBSS medium, to which 100 µM
EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid) was added to chelate any
residual Ca2+ ions. This medium was added to the cells just before recording to avoid leaks from the
intracellular calcium stores.
Fluorescence was recorded using an inverted fluorescence confocal microscope (Zeiss LSM 510,
Göttingen, Germany) with a 25× oil immersion objective. Images were recorded at constant 10-s
intervals. Regions of interest corresponding to cells recorded were drawn to analyze the fluorescence
signal. To overcome putative differences of Ca2+ probe concentration between cells, we normalized the
fluorescence signal (F) of each cell by its starting basal fluorescence (F0). Data were processed using
OriginPro 7.5 (Origin Lab, Paris, France) and Prism 6.0 (Graphpad, San Diego, CA, USA) software.
4.6. Assessement of Lysosomal Membrane Permeabilization
Lysosomal membrane permeabilization (LMP) and lysosomal cathepsin B release were assessed by
lysotracker staining and immunofluorescence, respectively, and analyzed by fluorescence microscopy.
For LMP detection, cells were stained with lysotracker red (100 nM) in HBSS at 37 ◦C for 45 min. Cells
were then rinsed twice in HBSS. Fluorescence micrograph images were obtained using an inverted
fluorescence microscope with an ApoPLAN 63× objective. Images were recorded at constant 1-min
intervals. Regions of interest corresponding to cells recorded were drawn to analyze the fluorescence
signal, and its slope was calculated using GraphPad Prism software.
To visualize cathepsin B release in the cytosol, cells were untreated or treated with GA101 or
siramesine (a lysosomotropic agent), and immunofluorescence was performed. Cells were fixed in
Phosphate Buffer Saline (PBS) containing 4% w/v paraformaldehyde at 4 ◦C for 10 min and then
permeabilized in PBS supplemented with 5% Bovine Serum Albumin (BSA)/0.1% saponin for 5 min.
Cells were incubated with anti-cathepsin B in PBS/1% w/v BSA at 4 ◦C overnight. Cathepsin B was
revealed using secondary Alexa594-coupled donkey anti-goat Ab. Nuclei were stained using Hoechst
33258. Images were acquired using a Zeiss LSM 510 meta confocal microscope with an ApoPLAN
63× objective.
4.7. Western Blotting
Cell lysates were prepared using a lysis buffer containing protease and phosphatase inhibitors
(Cell Signaling Technology). The lysates were separated by SDS-PAGE and transferred to
Polyvinylidene fluoride (PVDF) membrane using an iBlot Gel Transfer System (Thermofisher Scientific).
The membranes were incubated with 5% nonfat milk w/v in PBS buffer for 1 h and then reacted
with the primary Ab in PBS/Tween buffer with 5% nonfat milk w/v by shaking at 4 ◦C overnight.
The appropriate second Abs conjugated to HRP was used to detect the protein of interest via Enhanced
Chemiluminescence (ECL) (Millipore).
4.8. RT-qPCR
Total RNA was isolated using the RNeasy kit (Qiagen, Les Ullis, France) and its concentration
was determined by Nanodrop. Quality and integrity of total RNA was assessed using the Bioanalyzer
(Agilent, Les Ullis, France). For real-time PCR, the reverse transcription (RT) reaction was carried
out with 1 µg of total RNA in a 20-µL mixture to generate first-strand complementary DNA
(cDNA) using PrimeScript RT reagent kit with genomic DNA (gDNA) Eraser (Takara, Nice,
France). All real-time PCR reactions were performed in a 20-µL mixture containing 1/2 volume
of cDNA preparation using PowerUp Sybr Green Master mix (Thermofischer Scientific) and Taq
Ozyme HS (Ozyme) according to manufacturer’s protocol. Quantitative PCR was performed
using appropriate primers (CD38 forward: TCA-GCC-ACT-AAT-GAA-GTT-GGG-A; CD38 reverse:
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CTG-GAC-CTG-TGT-GAA-CTG-ATG-G; TPC1 forward: GGA-GCC-CTT-CTA-TTT-CAT-CGT; TPC1
reverse: GGA-GCC-CTT-CTA-TTT-CAT-CGT; TPC2 forward: GTA-CCC-CTC-TTG-TGT-GGA-CG;
TPC2 reverse: GGC-CCT-GAC-AGT-GAC-AAC-TT). Real-time quantifications were performed
using the StepOnePlus Real-Time PCR System (Applied Biosystems, Thermofisher Scientific). The
fluorescence threshold value was calculated using StepOne software (Applied Biosystems).
4.9. Statistical Analysis
All data were expressed as means ± SE. The significance of differences was calculated using the
parametric t-test or one-way ANOVA test or the non-parametric Mann–Whitney U or Wilcoxon tests,
as appropriate (* p < 0.05).
5. Conclusions
In conclusion, this study provides new mechanistic insights into GA101-induced cell death,
including the important, complex role of Ca2+ signaling. The source of Ca2+ increase, as well as its
role in GA101-induced cell death, differed according to the cell type studied. Further investigations
are required to identify the biomarkers of Ca2+ involvement in GA101-induced cell death, in order to
design new, rational drug combinations to improve the clinical efficacy of GA101.
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